Richard Schilsky to Molecular Targeted Therapy
This is a "connection" page, showing publications Richard Schilsky has written about Molecular Targeted Therapy.
Connection Strength
3.767
-
Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies. J Oncol Pract. 2019 11; 15(11):575-583.
Score: 0.506
-
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol. 2016 Jan 10; 34(2):179-85.
Score: 0.388
-
Modernizing Eligibility Criteria for Molecularly Driven Trials. J Clin Oncol. 2015 Sep 01; 33(25):2815-20.
Score: 0.383
-
Improving evidence developed from population-level experience with targeted agents. Clin Pharmacol Ther. 2015 May; 97(5):478-87.
Score: 0.375
-
Precision cancer medicine: the future is now, only better. Am Soc Clin Oncol Educ Book. 2014; 61-9.
Score: 0.344
-
Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. Am Soc Clin Oncol Educ Book. 2013; 118-25.
Score: 0.321
-
Targeted therapy for cancer: asking the right questions. Oncology (Williston Park). 2012 Oct; 26(10):947-9.
Score: 0.315
-
Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol. 2011 Dec 06; 9(4):208-14.
Score: 0.298
-
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021 08 01; 39(22):2443-2451.
Score: 0.142
-
Response. J Natl Cancer Inst. 2016 Mar; 108(3):djw001.
Score: 0.100
-
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015 Nov; 107(11).
Score: 0.097
-
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015 Nov 10; 33(32):3817-25.
Score: 0.096
-
Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol. 2015 Aug; 26(8):1791-8.
Score: 0.094
-
Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809.
Score: 0.092
-
American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol. 2013 Dec 01; 31(34):4362-70.
Score: 0.085
-
Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Jul 11; 15(1):5837.
Score: 0.045
-
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019 10; 574(7776):127-131.
Score: 0.032
-
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019 05; 25(5):751-758.
Score: 0.031
-
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget. 2015 Jun 10; 6(16):14139-52.
Score: 0.024